FOLH1 and xerostomia: New onset grade I/II xerostomia was noted in 5/14 and this concern is addressed below in more detail A phase II with 225Ac-PSMA I&T q 8 weeks is now underway (NCT05219500) using 100 kBq/kg for dose 1, followed by dose de-escalation in responding patients (using investigator discretion).